Targeted Medical Pharma, a Los Angeles-based biotechnology company, has published a new whitepaper, Innovations in Pain Management, addressing a new way to curb the over-prescribing of opioids and NSAID pain relievers. Over-prescription of this kind is frequently deemed an “epidemic” across the U.S. and is particularly prevalent in Southern states like Louisiana. The study touts the effectiveness of a “medical food” called Theramine for chronic pain related to a variety of conditions including lower back pain issues, fibromyalgia and migraines. Targeted Medical Pharma claims that Theramine has been used effectively since 2004 as a replacement for or adjunct therapy to opioids and NSAIDs. Further, they claim that Theramine does not produce the same cardiovascular and gastrointestinal side effects as NSAIDs, nor is it addictive. Theramine has been the subject of two double-blind clinical trials which are published in the American Journal of Therapeutics. In both studies, Theramine showed a statistically significant reduction in inflammation and improvement in low back pain compared to both naproxen and ibuprofen and proved to be effective at increasing specific amino acid levels in study subjects.
Read the full release via Business Wire here.